

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MONTECALVO DAVID A _____ (Last) (First) (Middle) 530 HERMAN O. WEST DRIVE _____ (Street) EXTON PA 19341 _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol WEST PHARMACEUTICAL SERVICES INC [WST]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ <input checked="" type="checkbox"/> SVP, Glob Ops and Supply Chain	
			3. Date of Earliest Transaction (Month/Day/Year) 07/28/2020			
			4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person _____ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/28/2020		M		10,792	A	\$71.79	15,732.42	D	
Common Stock	07/28/2020		M		3,000	A	\$83.47	18,732.42	D	
Common Stock	07/28/2020		S		716	D	\$266.058	18,016.42	D	
Common Stock	07/28/2020		S		7,773	D	\$264.1315 ⁽¹⁾	10,243.42	D	
Common Stock	07/28/2020		S		2,881	D	\$265.1292 ⁽²⁾	7,362.42	D	
Common Stock	07/28/2020		S		138	D	\$265.8507 ⁽³⁾	7,224.42	D	
Common Stock	07/28/2020		S		3,000	D	\$265.9769 ⁽⁴⁾	4,224.42	D	
Common Stock	07/29/2020		M		5,358	A	\$83.47	9,582.42	D	
Common Stock	07/29/2020		S		3,273	D	\$270.7038	6,309.42	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$71.79	07/28/2020		M			10,792	02/23/2017	09/26/2026	Common Stock	10,792	\$0.00	0.00	D	
Stock Options (Right to buy)	\$83.47	07/28/2020		M			3,000	02/21/2018	02/21/2027	Common Stock	3,000	\$0.00	8,144	D	
Stock Options (Right to buy)	\$83.47	07/29/2020		M			5,358	02/21/2018	02/21/2027	Common Stock	5,358	\$0.00	2,786	D	

Explanation of Responses:

- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from \$263.80 to \$264.79, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from \$264.80 to \$265.77, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from \$265.80 to \$265.87, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from \$265.9762 to \$265.9769, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

Remarks:

Ryan Metz as Agent for David A. Montecalvo 07/29/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.